In an interview with PharmaShots, Eric Pearlman, Associate Vice President, Global & US Medical Affairs at Eli Lilly shared his views on the initiation of the patients enrollment in P-IV (CHALLENGE-MIG) head-to-head trial of Emgality for episodic migraine in adults Shots: The company initiate the patients' enrollment for the P-IV (CHALLENGE-MIG) head-to-head trial to evaluate the efficacy and safety of Emgality vs Nurtec ODT…